Home › Trials › NCT06705803
Clinical trial Recruiting at 2 sites Observational Ages 22 and up Men only

Registry for prostate cancer ablation data

Official title: Prostate Ablation Registry and Database for Information, Surveillance, and Evaluation (PARADISE)

Run by University of Chicago · NCT06705803 · Data updated 2026-11-12

This study is creating a database to collect information from men with prostate cancer who are having ablation treatments to see how well these procedures work and what side effects they may cause.

Quick facts

Study typeObservational
Ages22 Years and up
SexMen only
Enrollment3000 (estimated)
SponsorUniversity of Chicago
Academic / other
Locations2 sites (Hyde Park, Illinois and 1 other locations)
StatusRecruiting
StartedJune 21, 2024
Main results expectedJune 2029
Study endsJune 2029
Registry record updatedFebruary 2, 2026
Trial IDNCT06705803 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are men aged 22 and older with a histologic diagnosis of prostate cancer who are scheduled to undergo or have undergone prostate ablation.

Probably not a fit

Patients under 21 years of age or those not undergoing prostate ablation will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study aims to create a comprehensive database and registry for patients with prostate cancer who are undergoing prostate ablation procedures. It focuses on collecting data regarding the efficacy and side effects of various ablation techniques, including cryotherapy and high-intensity focused ultrasound. By gathering this information, the study seeks to evaluate the long-term outcomes of prostate ablation as a treatment option that balances active surveillance and radical therapy. The registry will include patients who are either scheduled for or have already undergone ablation as part of their clinical care.

Why it matters

Potential benefit: If successful, this study could provide valuable insights into the long-term effectiveness and safety of prostate ablation, potentially improving treatment options for prostate cancer patients.

How similar studies have gone: While there is ongoing interest in prostate ablation techniques, this registry approach is relatively novel and aims to fill gaps in existing data regarding long-term outcomes.

Who can join: the full rules

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Male sex
* ≥22 years of age
* Histologic diagnosis of prostate cancer
* Scheduled to undergo or have already undergone ablation of the prostate as part of routine clinical care or any ongoing clinical trials
* Prostate ablation performed with any of the following energy sources: cryotherapy, high-intensity focused ultrasound, irreversible electroporation, laser, microwave, radiofrequency ablation, or photodynamic therapy. Newer methods and instrumentation continue to be developed to ablate tissue, and these energy sources can be entered into the registry as clinical use begins

Exclusion Criteria:

* Under 21 Years of age.

Where it's running

  • The University of Chicago
    Hyde Park, Illinois, United States     Recruiting
  • The University of Cinncinatti
    Cincinnati, Ohio, United States     Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov ↗ Find more trials like this →
Browse more
Prostate Cancer 1464University of Chicago 1046
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.